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ABSTRACT 
AIm: To describe effectiveness of deep brain stimulation of subthalamic nucleus (DBS STN) on physical, emotional, cognitive functions and 
daily activities in Parkinson’s patients. 
mAterIAl and methOds: Ten patients (51.20 ±10.20 yr.) were assessed three times. The Time Up and Go Test, 12 m Walking Test and Chair 
Stand Test were used to assess mobility and balance. Purdeu Pegboard and hand writing tests were used to evaluate hand function. The 
Hospital Anxiety and Depression Scale (HAD) was used to detect depressive symptoms and anxiety score. The Unified Parkinson\’s Disease 
Rating Scale (UPDRS) and Hoehn &Yahr Scale were also used. The Schwab and England Test was used to evaluate the daily activities (ADL).     
results: The results showed that all the patients’ mobility and balance ability improved after surgery (p<0.05). Depressive symptoms / anxiety 
scores were found to be lower than before surgery (p<0.05). There were differences in terms of ADL and UPDRS scores after surgery (p<0.05). 
At six month after surgery; depressive symptoms decreased by 78%. ADL and UPDRS motor and total scores improved by 190%, 72%, and 78% 
respectively.   
COnClusIOn: STN DBS is an effective treatment to improve physical functioning, emotional status and daily activities in Parkinson’s patients. 
However, it did not show any positive effect on cognitive function.      
KeywOrds: Parkinson’s disease, Subthalamic nucleus, Balance, Mobility, Emotional status, Daily living activities 
ÖZ 
AmAÇ: Parkinson hastalarında Subtalamik Çekirdek Derin Beyin Stimülasyon’un (STN DBS) fiziksel, emosyonel, kognitif fonksiyon ve günlük 
yaşam aktiviteleri üzerine etkilerini değerlendirmek. 
yÖntem ve GereÇ: STN DBS cerrahisi uygulanan 10 hasta cerrahi öncesi, cerrahi sonrası 3. ve 6. ayda değerlendirilmiştir. Mobilite ve denge 
yeteneği Süreli Kalk Yürü Testi, 12 m Yürüme Testi, Otur-Kalk Testi ile el fonksiyonları Purdue Pegboard Testi ve el ile yazı yazma testleri ile 
ve emosyonel statü Hastane Anksiyete ve Depresyon Ölçeği (HAD) ile değerlendirilmiştir. Parkinson hastalığının klinik şiddetini belirlemek 
için Birleşik Parkinson Hastalığı Değerlendirme Ölçeği (BPHDÖ), evreyi belirlemede Hoehn&Yahr Ölçeği, günlük yaşam aktivitelerinin (GYA) 
değerlendirilmesinde Schwab ve England GYA ölçeği kullanılmıştır.      
BulGulAr: Olguların yaş ortalaması 51,20 ±10,20 yıldır. Sonuçta mobilite ve denge yeteneği test sonuçlarında cerrahi sonrasında anlamlı 
gelişmeler elde edilmiştir (p<0.05). Depresyon / anksiyete skorları cerrahi öncesine göre daha düşük bulunmuştur (p<0.05). Cerrahi sonrasında 
GYA ve BPHDÖ skorları arasında istatistiksel anlamlı farklılık bulunmuştur (p<0.05). Tedavinin etkinliği açısından incelendiğinde cerrahi sonrası 
6. ayda depresif semptomlarda %78 azalma, GYA %190, BPHDÖ motor bulgularda %72, BPHDÖ toplam skorda %78 oranında gelişme elde 
edilmiştir.   
sOnuÇ: STN DBS cerrahisinin parkinson hastalarında fiziksel fonksiyon, emosyonel statü ve GYA üzerine iyileştirici yönde etkileri olduğunu, 
fakat kognitif fonksiyonlar üzerine etkisi olmadığını göstermiştir.       
AnAhtAr sÖZCÜKler: Parkinson hastalığı, Subtalamik çekirdek, Denge, Mobilite, Emosyonel statü, Günlük yaşam aktiviteleri
The Influence of Subthalamic nucleus Deep Brain 
Stimulation on Physical, Emotional, Cognitive 
Functions and Daily Living Activities in Patients with 
Parkinson’s Disease 
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InTRoduCTIon
Parkinson’s disease (PD) is a progressive movement disorder 
ensuing from dopaminergic depletion of the basal ganglia, 
substantia nigra pars compacta. The resulting disruption of 
the motor circuit that connects the basal ganglia to the motor 
cortex leads to the clinical manifestations of tremor, rigidity, 
bradykinesia and postural instability. The management of 
Parkinson’s disease is mainly pharmacological. Levodopa 
and dopamine agonists are able to provide adequate 
symptomatic control in the first 5–10 years of therapy. 
However, long-term evolution is marred in the majority of 
patients by complications, such as fluctuations in the motor 
state and dyskinesias (16, 19).  In recent years, surgery 
has been revitalized for the treatment of patients with 
uncontrollable motor complications. The aim of surgery is 
mainly to decrease the pathological influences of abnormal 
neuronal drive from the subthalamic nucleus (STN) that 
characterize the Parkinsonian state. Deep brain stimulation 
(DBS) mimics the effect of lesions (thalamotomy, pallidotomy, 
etc.) with less risk of permanent neurological deficits (11). 
Deep brain stimulation (DBS) of the subthalamic nucleus 
(STN) is an effective treatment to improve motor function, 
daily living activities and emotional status in patients with 
advanced Parkinson’s disease. STN DBS, however, fails to 
address numerous symptoms that are disabling in advanced 
PD, such as levodopa-refractory axial motor disturbances. 
Several studies have shown a substantial beneficial effect 
of DBS of the STN in advanced Parkinson’s disease 12–24 
months post-operatively (13, 17, 23).  The other studies with 
respect to short- and long-term efficacy of STN-DBS have 
shown marked improvements in motor function as well as a 
reduction of antiparkinsonian drug treatment. Similar results 
have been reported in a smaller number of patients by a few 
other groups (8, 23). The aim of this study was to describe the 
effects of deep brain stimulation of subthalamic nucleus (DBS 
STN) on physical, emotional, cognitive functions and daily 
living activities in patients with Parkinson’s disease. 
MATERIAL and METHodS  
Patient Group 
We studied 10 (5 male-5 female) consecutive patients who 
underwent bilateral stimulation of the subthalamic nucleus 
between January 2008 and January 2010. The selection 
criteria were clinically diagnosed Parkinson’s disease, severe 
levodopa-related motor complications despite optimal 
adjustment of antiparkinsonian medication, no surgical 
contraindications, no dementia or major ongoing psychiatric 
illness and no other neurological disorders. The ethics 
committee of Pamukkale University in Turkey approved 
the study, and all the patients gave their written informed 
consent. The characteristics of the patients are summarized 
in Table I. 
Surgery Procedure
All STN DBS procedures were performed by one neurosurgeon 
in two stages: (1) insertion of bilateral electrodes under 
local anaesthesia using microelectrode recording, and (2) 
connection of the electrodes to pulse generators under 
general anaesthesia, performed approximately 1 day after 
lead placement. The operative technique was described in 
details elsewhere (5). The subthalamic nuclei were localized 
stereotactically by magnetic resonance imaging (MRI), and 
microelectrode recordings were performed to define STN. 
The quadripolar electrodes (Medtronic 37601 Activa PC) were 
implanted bilaterally in all patients. Surgery was performed 
with local anesthesia and clinical effect on rigidity and tremor 
was tested under stimulation using a macroelectrode. All 
patients underwent MRI postoperatively for the assessment of 
surgical complications. A programmable pulse generator was 
implanted subcutaneously under general anesthesia on the 
second day after implantation of the electrodes. Stimulation 
settings and medication were progressively adjusted. 
Clinical Assessment
Patients were evaluated preoperatively and postoperatively 
at third and sixth months. Unblinded assessments were 
performed when patients had taken no medication for 8 to 12 
hours (off medication) and during periods of maximal clinical 
benefit after the administration of a dose of liquid levodopa 
that was 50 percent higher than the usual morning dose of 
dopaminergic treatment (on medication). Postoperatively, 
patients were assessed during stimulation. 
Outcome Measures 
The physical therapist assessed the patient with clinical 
performance tests, and the same PT assessed all patients in 
all test situations. 
The Timed Up & Go (TUG)
The subject sits in an armchair (seat height of 46 cm) with the 
back against the chair and arms resting on the chair’s arms. 
The instruction “Go’’ initiates the subject to stand up and walk 
at a comfortable pace to a line 3 meters away, where both 
feet should pass the line before the subject turns around 
and walks back to sit down again. Timing commences when 
the subject’s back is leaving the back of the chair, and stops 
when the buttock reaches the seat of the chair. Average time 
required to complete the test TUG is reported (7).    
Chair-Stand Test
The time required to stand up from a chair and to sit down 
five times consecutively as fast as possible is registered. The 
subject sits in an armchair (seat height of 46 cm) with the 
back against the chair, and with arms folded across the chest. 
The subject’s regular footwear is worn. The test begins with 
the commando “Start now’’. Timing commence when the 
subject’s back is leaving the back of the chair, and stops when 
the subject’s buttock reaches the seat for the fifth time. One 
trial is performed. The average time required to complete the 
test is reported (7).   
12 Meters Walking Test
The subject is standing still and then walks at a comfortable 
(preferred) speed straight forward. The subject’s regular 
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footwear is used. Timing commences after the command 
“Go’’ and stops when the subject passes the mark for twelve 
meters. One trial is performed. The average time required to 
complete the test time is reported (7).   
Unified Parkinson’s Disease Rating Scale (UPDRS)
Patients were clinically assessed using the UPDRS. Different 
scores were extracted from this scale:  the psychological status 
(items 1 and 4 of the UPDRS I), the daily living activities (ADL) 
score (items 5 and 17 of the UPDRS II), the motor score (items 
18–31 of the UPDRS III), the dyskinesias score (items 32–35 of 
the UPDRS IV), the total UPDRS score comprised between 0 
and 108, and the worst value was 108 (6).    
Hoehn&Yahr Scale (H&Y)
H&Y is a commonly used system for describing how the 
symptoms of PD progress. The H&Y original scale included 
stages 1 through 5 with Stage 0: no signs of disease, stage 
1: unilateral symptoms only, stage 2: bilateral symptoms and 
impairment of balance, stage 3: balance impairment, mild to 
moderate disease and physically independent, stage 4: severe 
disability, but still able to walk or stand unassisted, stage 5: 
needing a wheelchair or bedridden unless assisted (6).     
Schwab and England Daily Living Activities Test (ADL)
The Schwab and England Test was used to evaluate the 
daily living activities (ADL). The test rates the patient’s 
ability to perform ADL from 100% (essentially normal) to 0% 
(vegetative) (6).     
Purdeu Pegboard Test 
The Purdue Pegboard test measures dexterity for two types of 
activity: one, involving the gross movement of arms, hands, 
and fingers and the other in primarily fingertip dexterity. The 
test consists of four parts: right hand, left hand, both hands 
and assembly. Their total is counted (20).    
Hand Writing Tests
The sentence was selected and the writing task was performed 
using by dominant hand. Average time required to complete 
the test is reported. 
Hospital Anxiety and Depression Scale (HAD)
HAD was applied to detect depressive symptoms and to 
describe anxiety score (10).     
Hodkinson Abbreviated Mental Test (AMT)
Cognitive performance was measured with AMT. AMT 
consisting of 10 questions to test time and place, orientation, 
memory and arithmetic skills (1).     
All participants gave informed consent and the study was 
approved by the ethical board committee of Pamukkale 
University Medical Faculty (Ref no: 67 date, 03.04.2009). This 
study was supported by the Pamukkale University Scientific 
Research Projects Foundation (Ref no:2009SBE003). 
Statistical Analyses
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS version 13.0). The 
Wilcoxon rank sum test was applied for comparison between 
the mean scores preoperatively and at the postoperative 
assessment. The effects of bilateral STN DBS on UPDRS, 
H&Y, ADL, HAD, AMT, hand function, mobility and balance 
assessment tests were analyzed using the paired t- test. A 
level of p<0.05 was considered significant. 
RESuLTS
The demographics and clinical characteristics of patients at 
baseline are shown in Table I. The results of this study showed 
that all the patients’ mobility and balance ability significantly 
improved at the third month and sixth month after surgery 
(p<0.05). The mobility and balance assessment values at the 
baseline, third month and sixth month are shown in Table II.        
The hand function tests were significantly improved between 
the three assessments. Post hoc comparisons revealed that 
the comparison between preoperative and third month 
(p<0.05) and sixth month (p<0.05) were significant. The hand 
function tests are shown in Table III. 
The anxiety and depression scores of thought disorders 
significantly decreased with month (p<0.05). Post hoc 
anxiety scores comparison revealed that differences were 
significant between before surgery and third month after 
surgery (P=0.000) and between before surgery and sixth 
month postop (P=0.003). Depressive symptoms score was 
found to be lower after surgery than before surgery (p<0.05). 
Compared to the preoperative period, third month and sixth 
month mental status scores were not significantly different 
(p>0.05). Mood status score and mental status score are 
shown in Table IV. 
Compared to the preoperative baseline, third month and sixth 
month score; the UPDRS-I, II, III, and IV scores in both the ‘on’ 
and ‘off’ states were significantly better (p<0.05). All aspects of 
the motor symptoms including speech, tremor, rigidity, and 
postural stability were significantly improved after surgery 
(p<0.05). Compared to the preoperative, third month and 
sixth month; the ADL scores were significantly better (p<0.05). 
At 6 months after surgery, the ADL score was increased from 
20.60±1.64 to 60.83±2.85 (Paired t-test) (p<0.05). H&Y score 
was decreased from 4.20 ± 0.63 to 2.33 ± 1.50 at sixth month 
postop. Levodopa equivalents intake (LED) was reduced 
from a mean of 445. 00 ± 369. 27 to 208. 33 ± 281.36 mg/day 
after six months. Compared to the preoperative, third month 
and sixth month; the UPDRS total scores were significantly 
improved (p=0.000) (Table V). 
dISCuSSIon
In patients with advanced Parkinson’s disease who were 
followed prospectively, six month bilateral stimulation of 
the subthalamic nucleus led to significant postoperative 
improvements in all parkinsonian motor signs that were 
assessed. STN DBS is superior to best medical therapy in 
Turkish Neurosurgery 2011, Vol: 21, No: 2, 140-146 143
Altug F, et al: Subthalamic Nucleus Deep Brain Stimulation
of levodopa was significantly reduced (P<0.001) (18). In our 
results, LED was reduced from a mean of 445.00 ± 369.27 to 
208.33 ± 281.36 mg/day after six months. 
Postural instability is one of the cardinal symptoms of 
Parkinson’s disease (PD), and persons with PD have an increased 
risk of falling. Most falls occur during functional activities, e.g. 
walking and turning (12).  STN DBS provides significant motor 
improving motor function, emotional status and daily living 
activities in PD patients with motor complications. The 
improvements over baseline were sustained six months after 
surgery (14).  STN stimulation has consistently been shown 
to attenuate the motor symptoms of PD and to decrease 
the daily dosage of medication, thus reducing drug related 
motor complications and according to some reports (3). 
Rodriguez Oroz et al., found that STN stimulation daily dosage 
Table I: Demographic Characteristics of Patients Included in Study
   Min-Max X±Sd
Age (yr) 31.00 – 62.00 51.20 ± 10.20
Height  (cm) 150 – 170 164 ± 0.06
Weight (kg) 47.00 – 104. 00 67.30 ± 17.99
BMI (Kg/m2) 17.72 – 35.99 24.75 ± 5.66
Duration of disease (yr) 9.00 – 25.00 13.40 ± 5.12
Duration of using levodopa (yr) 9.00 – 25.00 12.50 ± 5.14
Equivalent daily dose of levodopa (mg) 0 – 1000 445.00 ± 369. 27
    P- Value













Timed Up&Go Test (sec) 43.20 ± 22.38 19.90 ± 21.46 27.00 ± 32.21 P=0.008* P=0.043* P=0.157
Chair-Stand Test 
(Repetition/30sn)
  4.60 ± 12.09 9.50 ± 4.35 11.16 ± 8.47 P=0.003* P=0.037* P=0.807
12m Walking Test (sec) 72.90 ± 37.50 21.80 ± 28.56 18.50 ± 16.93 P=0.002* P=0.028* P=0.417
* Paired t- test.
   P- Value














     Right hand 5.30 ± 3.65 10.20 ± 2.65 8.66 ± 3.98 P=0.000* P=0.090 P=0.112
     Left hand 5.50 ± 3.68 9.80 ±3.35 9.16 ± 5.26 P=0.000* P=0.036* P=0.235
    Both hands 4.30 ± 3.02 7.30 ± 3.23 6.16 ± 4.49 P=0.000* P=0.074 P=0.130
    Assembly 2.70 ± 1.56 5.80 ± 2.29 4.66 ± 3.20 P=0.000* P=0.027* P=0.058
Hand Writing Tests  52.70 ± 29.45 41.80 ± 28.35 64.33 ± 57.40 P=0.036* P=0.290 P=0.083
 * Paired t- test.
Table II: Mobility and Balance Assessment 
Table III: Assessment of Hand Function
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They found that bilateral and unilateral STN DBS was effective 
on mobility and gait function (7). According to our results, 
mobility and balance ability significantly improved at three 
months and six months after surgery (P<0.05). Several studies 
have demonstrated significant improvement of bradykinesia, 
rigidity, hand function in PD after bilateral STN DBS. Tabbal 
et al. found that STN DBS reduces rigidity (P<0.05) with a 25 
– 83% decrease in UPDRS bradykinesia ratings with bilateral 
benefits for patients with advanced Parkinson’s disease, while 
reducing dyskinesia and motor fluctuations. Several study 
shows that 12 months follow-up after stimulation resulted in 
improved scores for akinesia, rigidity, tremor, impairment of 
arising from chair, gait and postural instability, when patients 
were evaluated off in the medication and on medication state 
(15).  Kelly investigated the effects of unilateral and bilateral 
subthalamic nucleus stimulation on gait and mobility in PD. 
    P- Value














Anxiety status 16.60 ± 4.62 4.40 ± 3.94 4.83 ±2.04 P=0.000* P=0.003* P=0.165
Depression status 13.60 ± 6.48 4.40 ± 2.54 2.83 ± 2.48 P=0.001* P=0.052 P=0.490
Mental Status 8.60 ± 1.42 8.80 ± 1.87 8.50 ± 1.22 P=0.509 P=0.661 P=0.695
 * Paired t- test.
    P- Value












3rd – 6th 
month
      ADL 20.60 ± 1.64 60.40 ± 2.79 60.83 ± 2.85 P=0.000* P=0.001* P=0.341
      H&Y 4.20 ± 0.63 2.80 ± 0.91 2.33 ± 1.50 P=0.000* P=0.020* P=0.741
     UPDRS
Mood status (Part I) 4.60 ± 3.50 2.50 ± 3.06 1.33 ± 2.33 P=0.016* P=0.007* P=0.175
ADL(on) (Part II) 27.10 ± 13.80 9.80 ± 5.78 18.50 ± 10.59 P=0.000* P=0.050* P=0.629
ADL(off) (Part II) 37.10 ± 9.82 15.00 ± 9.74 15.66 ± 9.66 P=0.000* P=0.002* P=0.092
Motor scores(Part III) 35.40 ± 13.92 11.80 ± 10.70 9.50 ± 10.25 P=0.000* P=0.000* P=0.517
     Speech 2.70 ± 1.15 1.10 ± 0.99 0.83 ± 0.75 P=0.001* P=0.011* P=0.175
     Tremor 2.80 ± 1.47 0.80 ± 0.91 0.33 ± 0.51 P=0.000* P=0.002* P=0.076
     Rigidity 2.50 ± 0.40 0.70 ± 0.30 0.33 ± 0.51 P=0.001* P=0.003* P=0.465
     Postural stability 2.10 ± 1.10 0.90 ± 0.99 0.16 ± 0.40 P=0.000* P=0.001* P=0.076
UPDRS Diskinesias   
(Part IV) 
9.40 ± 1.64 2.10 ± 2.28 3.16 ± 3.37 P=0.000* P=0.003* P=0.045*
   UPDRS total 120.70 ± 39.42 41.80 ± 28.54 25.33 ± 20.23 P=0.000* P=0.000* P=0.657
   Daily L-dopa (mg) 445.00 ± 369. 27 235.00 ± 331. 49 208.33 ± 281. 36 P=0.028* P=0.356 P=0.419
 * Paired t- test.
Table IV:  Assessment of Mood Status and Mental Status
Table V:  Assessment of Parkinsonian Symptoms
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with consistent and stable improvements in motor physical, 
emotional and daily living activities in patients with PD. 
Cognitive function remained unchanged after STN surgery. 
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STN DBS, and the performance on the Purdue Pegboard 
test improved by 75% (21). We have found that the Purdeu 
Pegboard test score and hand writing test score significantly 
improved after postoperative six months (P<0.05). 
The mood strongly affects the functional status of patients 
with a chronic disease. Depression is a frequent complication 
of PD. Wang et al. stated that the Self-Rating Depression Scale 
scores decreased notably within 6 months postoperatively 
(P<0.05), and the Hamilton Rating Scale for Depression scores 
decreased notably within 3 months postoperatively (P<0.05) 
while in the STN- DBS group, the correlation between the 
UPDRS-III and SDS scores was significant at 3 months and 6 
months postoperatively (24). These results imply that the 
improvement in the motor symptoms caused by the STN–
DBS relieved the depressive mood of PD patients remarkably 
in the short term. Similar results are explained by Martinez-
Martin et al. (12). Our results are similar to with literature. In 
the present literature, the effects of STN DBS on cognitive 
functions and behaviors is not well known. Comparisons 
between preoperative and postoperative (from 3 to 12 months 
after surgery) evaluations have shown minor improvements 
in frontal lobe function. On the other hand, preoperative 
scores between one year and three years after surgery is not 
significantly better (4).  In this study, the AMT score was not 
significantly different at six months after surgery.
DBS (STN-S) is an effective treatment for functional capacity 
in PD. The Schwab and England scale has been used in other 
studies to assess the effects of surgical treatment in patients 
with PD in both the on-medication and off-medication states. 
Deep-brain stimulation of the thalamus has resulted in long-
term improvement in tremor and activities of daily living. In 
the STN-S group, all disability indicated that improvement 
at twelfth month as measured by a decrease in the UPDRS-
ADL score of 52% (p<0.001) with respect to the preoperative 
value. The FIM score increased after surgery by about 8% 
from baseline (2). In another study, the patients’ scores at 
five years for motor function while off medication improved 
by 54% compared with the baseline (P<0.001) and those for 
activities of daily living improved by 49% (P<0.001) (9). Tir 
et al. reported a decrease by 43% in the Unified Parkinson’s 
Disease Rating Scale Part III score twelve months after surgery 
while the Unified Parkinson’s Disease Rating Scale Part II 
score (activities of daily living) decreased by 34%, and the 
severity of dyskinesia-related disability decreased by 61% 
(22).  Our results are in line with the literature. UPDRS scores 
significantly decreased six months after surgery. Speech, 
tremor, rigidity and postural stability were significantly 
improved after surgery (p<0.05). At 6 months after surgery, 
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